L. acidophilus

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Lactobacillus acidophilus has been most studied in preclinical models of metabolic disease and gut-inflammatory conditions, with mechanistic emphasis on gut microbiota modulation, intestinal barrier integrity, and microbe-derived metabolites. Multiple mouse/rat studies examine high-fat diet (HFD)–induced obesity/insulin resistance and dextran sulfate sodium (DSS)–induced colitis, often integrating 16S rRNA profiling and targeted/untargeted metabolomics (short-chain fatty acids, SCFAs). A separate, more oncology-focused line of work investigates prophylaxis in NAFLD-associated hepatocellular carcinoma (NAFLD-HCC) using chemically induced and orthotopic mouse models, including germ-free experiments and testing of bacterial conditioned media and isolated metabolites. In parallel, food-science reviews emphasize L. acidophilus as a probiotic in fermented dairy products, focusing on viability thresholds and general health claims, while the human evidence in the set is limited and includes an incompletely reported randomized trial in a menopause/bone-health context.

The strongest evidence in these abstracts supports that L. acidophilus can improve host metabolic and inflammatory phenotypes in animal models, plausibly via barrier protection and metabolite-mediated signaling. In HFD-fed mice, supplementation is associated with reduced weight gain/adiposity, improved insulin resistance and lipid parameters, decreased endotoxemia, and suppression of inflammatory signaling (e.g., TLR4/NF-κB), with fecal transfer experiments suggesting a microbiome-mediated component. In DSS colitis rats, increased L. acidophilus abundance (including via FMT) and direct gavage are linked to reduced inflammatory cytokines, improved epithelial/goblet cell features, and increased acetate. For NAFLD-HCC, the most mechanistically specific evidence is that L. acidophilus secretes non-protein small molecules—highlighting valeric acid—which increases in portal/liver compartments, improves intestinal barrier integrity, and suppresses tumorigenesis in multiple mouse models, with proposed signaling through hepatocyte GPR41/43 and inhibition of Rho-GTPase pathways.

Key gaps include limited and incomplete human clinical evidence for most claimed benefits, uncertainty about strain specificity and dosing (including viability, formulation, and duration), and the need for replication across independent laboratories and diverse models. Mechanistically, while SCFAs (acetate, butyrate, valerate) and exopolysaccharides (EPS) are implicated, more work is needed to establish causal pathways in humans, define pharmacokinetics/biogeography of metabolites (gut lumen vs portal vs systemic), and clarify whether benefits require live organisms versus postbiotics. Future research priorities include well-powered randomized controlled trials with standardized endpoints (metabolic, inflammatory, liver outcomes), head-to-head comparisons of strains and delivery matrices (e.g., fermented foods vs capsules), safety and long-term colonization/engraftment studies, and translational validation of the NAFLD-HCC prophylaxis findings beyond mouse models.

1. What conditions has L. acidophilus been studied for?

  • NAFLD-associated hepatocellular carcinoma (NAFLD-HCC) (prevention/prophylaxis) in multiple mouse models (DEN + HFHC diet; DEN + CDHF diet; orthotopic allografts; germ-free tumorigenesis models).

  • Obesity and metabolic syndrome features in high-fat diet (HFD) mice: body weight/fat mass, insulin resistance, dyslipidemia, inflammation, and fatty liver-related outcomes.

  • Ulcerative colitis (UC)/colitis in DSS-induced rodent models, including studies where L. acidophilus was identified as a “driver” bacterium in a drug-response microbiome shift and then tested directly by gavage.

  • Adjunct to cancer therapy (oncolytic virotherapy) in mouse hepatocellular carcinoma models receiving VSVΔ51, focusing on microbiota interactions and gut barrier integrity.

  • Antibacterial activity (in vitro) against otitis media-associated bacteria, including combination testing with ciprofloxacin.

  • Bone/menopause-related outcomes in a 12-week randomized controlled trial (abstract is truncated, but it reports serum calcium changes and bone metabolism biomarkers).

  • General probiotic/fermented dairy applications (review-style abstract): GI infections, cholesterol reduction, antimutagenic activity, “antitumor activity” attributed to starter bacteria cell wall components.

  • Aquaculture/animal health (shrimp and aquaculture water studies; abstracts are truncated but indicate immune response, disease resistance, microbiota effects).

2. Does it work in treating those conditions? Summarize the evidence.

  • NAFLD-HCC (mouse evidence: preventive benefit)

    • L. acidophilus supplementation suppressed NAFLD-HCC formation in HFHC-fed, DEN-treated mice; findings were also supported in orthotopic allografts and germ-free tumorigenesis models.

    • Mechanistic evidence: L. acidophilus conditioned medium inhibited growth of NAFLD-HCC human cells and mouse organoids; activity attributed to non-protein small molecules, with valeric acid identified as a top enriched metabolite. Valeric acid itself suppressed tumor formation in two mouse NAFLD-HCC models and was linked to improved intestinal barrier integrity and signaling via GPR41/43 and inhibition of the Rho-GTPase pathway.

    • Limitation: all efficacy outcomes described here are preclinical (mice/cells/organoids), not human clinical endpoints.

  • Obesity/insulin resistance (mouse evidence: benefit)

    • In HFD-fed mice, L. acidophilus reduced body weight, fat mass, inflammation, and insulin resistance, and was associated with BAT activation and improved energy/glucose/lipid metabolism.

    • Microbiome and barrier findings: it reversed aspects of dysbiosis (e.g., reduced Firmicutes:Bacteroidetes ratio and endotoxin-bearing Gram-negative bacteria), improved intestinal barrier integrity, reduced metabolic endotoxemia, and inhibited TLR4/NF-κB signaling.

    • Transmissibility: anti-obesity effects were reported as transferable via fecal transfer from treated mice to HFD-fed mice, supporting a microbiome-mediated mechanism.

    • Another study of a specific strain (L. acidophilus YL01) and its exopolysaccharide (EPS) reported reductions in body weight and improvements in glucose/insulin resistance, dyslipidemia, liver function, and inflammation in high-fat mice; mechanism implicated increased acetic acid and butyric acid and activation of AMPK/ACC.

    • Limitation: these are animal studies; human efficacy is not established from the provided abstracts.

  • Ulcerative colitis/colitis (rodent evidence: benefit)

    • In DSS-induced colitis rats, a drug (evodiamine) improved colitis alongside microbiome changes; fecal transplant from treated rats alleviated colitis and increased L. acidophilus abundance and acetate.

    • Direct gavage with L. acidophilus reduced pro-inflammatory cytokines, increased goblet cells and antimicrobial peptides, modulated Firmicutes/Bacteroidetes ratio, and increased acetate.

    • A synbiotic approach (BLEPS-1 from Bifidobacterium longum + L. acidophilus) alleviated DSS-induced colitis more than either alone, with immunomodulatory effects on macrophage polarization (BLEPS-1 decreasing M1; L. acidophilus increasing M2; combination shifting toward M2) and metabolic shifts including short-chain fatty acid and aromatic amino acid metabolism.

    • Limitation: evidence is preclinical (DSS models), which may not predict human UC outcomes.

  • Adjunct to oncolytic virotherapy (mouse evidence: context-dependent benefit)

    • In mouse HCC models, VSVΔ51 efficacy was higher in the absence of microbiota, but VSVΔ51 also caused dysbiosis and reduced commensal Lactobacillus.

    • L. acidophilus supplementation conferred sensitivity to VSVΔ51 by restoring gut barrier integrity and microbiota homeostasis disrupted by the virus.

    • Interpretation: L. acidophilus may be beneficial as a supportive microbiome intervention in this specific preclinical therapy context.

  • Antibacterial activity (in vitro evidence: mixed)

    • L. acidophilus cell-free supernatant showed synergy with ciprofloxacin against Pseudomonas aeruginosa and Proteus mirabilis, but antagonism against Staphylococcus aureus and Klebsiella pneumoniae in checkerboard testing.

    • Limitation: in vitro synergy/antagonism does not necessarily translate to clinical outcomes, but it raises the possibility of strain/product-specific interactions with antibiotics.

  • Menopause/bone outcomes (human evidence: unclear from truncated abstract)

    • In a 12-week randomized trial, the probiotic group had a decrease in serum calcium, while hair calcium and bone metabolism biomarkers showed no notable changes (as reported in the truncated abstract).

    • Because key details are missing (product composition, endpoints, effect sizes), no firm conclusion about efficacy for bone health can be drawn from the provided text.

3. What health benefits does it have?

  • Gut barrier support and reduced endotoxemia/inflammation

    • Improved intestinal barrier integrity and reduced metabolic endotoxemia in HFD mice; inhibition of inflammatory signaling (TLR4/NF-κB) was reported.

    • In NAFLD-HCC models, valeric acid (linked to L. acidophilus) improved intestinal barrier integrity alongside tumor suppression.

    • In DSS colitis models, L. acidophilus reduced pro-inflammatory cytokines and increased goblet cells and antimicrobial peptides.

  • Metabolic benefits (preclinical)

    • Reduced body weight and fat mass; improved insulin resistance and lipid metabolism in HFD mice.

    • Strain-specific work (YL01) suggests EPS and/or microbiome-mediated increases in acetate/butyric acid may activate AMPK/ACC and improve lipid metabolism (gut–liver crosstalk).

  • Potential anti-tumor effects (preclinical)

    • Suppressed NAFLD-HCC formation in multiple mouse models; conditioned medium inhibited growth of NAFLD-HCC human cells and mouse organoids; valeric acid implicated via GPR41/43 and Rho-GTPase pathway inhibition.

    • Review-style abstract also notes “antitumor activity” associated with starter bacteria cell wall, though this is general and not specific to a clinical outcome.

  • Microbiome modulation

    • Reversal of certain dysbiosis features in obesity models (e.g., Firmicutes:Bacteroidetes ratio changes; reduced endotoxin-bearing Gram-negative bacteria).

    • In colitis models, increased acetate and microbiome shifts consistent with improved mucosal defense.

  • Possible supportive role during specific cancer therapies (preclinical)

    • Restored gut barrier integrity and microbiota homeostasis during VSVΔ51 oncolytic virotherapy, improving therapeutic sensitivity in a mouse HCC model.

4. Does it have any downsides or side effects?

  • Potential for context-dependent or product-dependent interactions

    • In vitro, L. acidophilus cell-free supernatant showed antagonism with ciprofloxacin against S. aureus and K. pneumoniae, suggesting that combining certain probiotic-derived products with antibiotics could theoretically reduce antibiotic activity against some organisms (clinical relevance unknown).

  • Human side-effect data are not provided in these abstracts

    • The obesity, NAFLD-HCC, UC, and oncolytic virotherapy findings are largely in animals; adverse events in humans cannot be inferred from these abstracts.

  • Bone/menopause trial signal (uncertain)

    • The truncated RCT abstract reports a decrease in serum calcium in the probiotic group with no notable changes in other bone-related markers; without full context, it is unclear whether this represents a clinically meaningful downside, a transient lab change, or a chance finding.

  • General limitations/considerations (not directly evidenced here)

    • These abstracts do not report classic probiotic risks (e.g., infections in severely immunocompromised individuals), so no evidence-based claim can be made from the provided text alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not evaluate human genetic variants that predict response or risk from L. acidophilus (i.e., no pharmacogenomic stratification).

  • Mechanistic receptor note (not pharmacogenomics evidence): One NAFLD-HCC study reports valeric acid binding to GPR41/43 to inhibit the Rho-GTPase pathway. This suggests a plausible biology where host variation in these receptors could matter, but the abstracts provide no data on genotype-dependent effects.

  • Other pathway notes without genetic stratification: TLR4/NF-κB signaling (obesity model) and IL6-JAK-STAT3 signaling affecting colonization (oncolytic virotherapy model) are mentioned mechanistically, but no variant-specific benefits/harms are tested.

References

  1. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid.
    Harry Cheuk-Hay Lau, Xiang Zhang, Fenfen Ji, Yufeng Lin, Wei Liang, Qing Li, Danyu Chen, Winnie Fong, Xing Kang, Weixin Liu, Eagle Siu-Hong Chu, Queena Wing-Yin Ng, Jun Yu (2024) - EBioMedicine
  2. Lactobacillus acidophilus ameliorates obesity in mice through modulation of gut microbiota dysbiosis and intestinal permeability.
    Yongbo Kang, Xing Kang, Hao Yang, Haixia Liu, Xiaodan Yang, Qingqing Liu, Haixia Tian, Yang Xue, Peng Ren, Xiaoyu Kuang, Yue Cai, Mingwei Tong, Lin Li, Weiping Fan (2022) - Pharmacological research
  3. The Functional Roles of
    Huijuan Gao, Xin Li, Xiatian Chen, Deng Hai, Chuang Wei, Lei Zhang, Peifeng Li (2022) - Journal of microbiology and biotechnology
  4. Fermented milks and milk products as functional foods--a review.
    V K Shiby, H N Mishra (2013) - Critical reviews in food science and nutrition
  5. Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production.
    Meng-Xia Wang, Li Lin, Yong-Da Chen, Yu-Ping Zhong, Yi-Xuan Lin, Pei Li, Xing Tian, Bo Han, Zhi-Yong Xie, Qiong-Feng Liao (2020) - Pharmacological research
  6. Effects of
    Zhui Li, Weiwei Wang, Dan Liu, Yuming Guo (2018) - Journal of animal science and biotechnology
  7. Live
    Pei Li, Guoping Chen, Jiaxian Zhang, Chaoying Pei, Ying Chen, Jing Gong, Song Deng, Kaiwei Cai, Haiyan Li, Dawei Wang, Baochun Shen, Zhiyong Xie, Qiongfeng Liao (2022) - Food & function
  8. Lactobacillus acidophilus YL01 and its exopolysaccharides ameliorate obesity and insulin resistance in obese mice via modulating intestinal specific bacterial groups and AMPK/ACC signaling pathway.
    Chongjie Zhao, Linlin Xie, Jing Shen, Hongpeng He, Tongcun Zhang, Lizhuang Hao, Cai Sun, Xiaoyuan Zhang, Mian Chen, Fei Liu, Zhongyuan Li, Nan Wang (2025) - International journal of biological macromolecules
  9. Effects of daily probiotic supplementation with
    Iskandar Azmy Harahap, Małgorzata Moszak, Magdalena Czlapka-Matyasik, Katarzyna Skrypnik, Paweł Bogdański, Joanna Suliburska (2024) - Frontiers in nutrition
  10. The effect of yogurt fortified with
    Seyed Jalil Masoumi, Davood Mehrabani, Mehdi Saberifiroozi, Mohammad Reza Fattahi, Fariba Moradi, Masoud Najafi (2021) - Food science & nutrition
  11. Impact of
    Iskandar Azmy Harahap, Marcin Schmidt, Ewa Pruszyńska-Oszmałek, Maciej Sassek, Joanna Suliburska (2024) - Nutrients
  12. Effect of dietary supplementation with Moringa oleifera leaf extract and Lactobacillus acidophilus on growth performance, intestinal microbiota, immune response, and disease resistance in whiteleg shrimp (Penaeus vannamei).
    Zaenal Abidin, Huai-Ting Huang, Yeh-Fang Hu, Jui-Jen Chang, Chih-Yang Huang, Yu-Sheng Wu, Fan-Hua Nan (2022) - Fish & shellfish immunology
  13. Fermentation of Plant-Based Feeds with
    Nataly Oliveira Dos Santos Neves, Juliano De Dea Lindner, Larissa Stockhausen, Fernanda Regina Delziovo, Mariana Bender, Letícia Serzedello, Luiz Augusto Cipriani, Natalia Ha, Everton Skoronski, Enric Gisbert, Ignasi Sanahuja, Thiago El Hadi Perez Fabregat (2024) - Animals : an open access journal from MDPI
  14. A postbiotic exopolysaccharide synergizes with Lactobacillus acidophilus to reduce intestinal inflammation in a mouse model of colitis.
    Chong Ma, Xiaobin Zheng, Qian Zhang, Stephen James Renaud, Hansheng Yu, Yaning Xu, Yuchun Chen, Jing Gong, Yonghua Cai, Yanjun Hong, Hao Li, Qiongfeng Liao, Ying Guo, Liang Kang, Zhiyong Xie (2025) - International journal of biological macromolecules
  15. Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma.
    Jiayu Zhang, Jinneng Yang, Jinyan Luo, Weili Wu, Haidan Luo, Wenxia Wei, Haimei Lyu, Yuzhi Wang, Hairong Yi, Yijing Zhang, Zongmin Fan, Haiwen Lyu, Vishnu Priya Kanakaveti, Baifu Qin, Ping Yuan, Runxiang Yang, Haipeng Zhang, Tao Zuo, Dean W Felsher, Mong-Hong Lee, Kai Li (2025) - Nature communications
  16. Effects of Lactobacillus acidophilus AC on the growth, intestinal flora and metabolism of zebrafish (Danio rerio).
    Haoyu Qiu, Ling Huang, Hanying Wang, Chenzhi Tao, Zhiqiang Ran, Jiahang Xu, Haofeng Sun, Ping Wang (2024) - Fish & shellfish immunology
  17. Lactobacillus acidophilus VB1 co-aggregates and inhibits biofilm formation of chronic otitis media-associated pathogens.
    Ammar R Algburi, Shireen M Jassim, Igor V Popov, Richard Weeks, Michael L Chikindas (2024) - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
  18. Lactobacillus acidophilus LA14 Alleviates Liver Injury.
    Longxian Lv, Chunyan Yao, Ren Yan, Huiyong Jiang, Qiangqiang Wang, Kaicen Wang, Siqi Ren, Shandong Jiang, Jiafeng Xia, Shengjie Li, Ying Yu (2021) - mSystems
  19. Alternative to antibiotic growth promoters: beneficial effects of
    Youssef A Attia, Shereen Basiouni, Nisreen M Abdulsalam, Fulvia Bovera, Afaf A Aboshok, Awad A Shehata, Hafez M Hafez (2023) - Frontiers in veterinary science
  20. Effect of Lactobacillus (L. acidophilus NCIB1899, L. casei CRL 431, L. paracasei LP33) fermentation on free and bound polyphenolic, antioxidant activities in three Chenopodium quinoa cultivars.
    Jigang Zhang, Xudong Huang, Jianghua Cheng, Chuyan Wang (2023) - Journal of food science


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!